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Numerous single nucleotide polymorphisms (SNPs) have been found in recent genome wide association
studies (GWAS) to be associated with subtle plasma triglyceride (TG) variation in normolipidemic subjects.
However, since these GWAS did not speciﬁcally evaluate patients with rare disorders of lipoprotein
metabolism—‘hyperlipoproteinemia’ (HLP)—it remains largely unresolved whether any of these SNP determi-
nants of modest physiological changes in TG are necessarily also determinants of most HLP phenotypes. To
address this question, we evaluated 28 TG-associated SNPs from GWAS in 386 unrelated adult patients with
one of ﬁve Fredrickson phenotypes (HLP types 2A, 2B, 3, 4 and 5) and 242 matched normolipidemic controls.
We found that several SNPs associated with TG in normolipidemic samples, including APOA5 p.S19W and
-1131T>C, TRIB1 rs17321515, TBL2 rs17145738, GCKR rs780094, GALNT2 rs4846914 and ANGPTL3
rs12130333, were signiﬁcantly associated with HLP types 2B, 3, 4 and 5. The ﬁndings indicate that: (i) the
TG-associated Fredrickson HLP types 2B, 3, 4 and 5 are polygenic traits; (ii) these Fredrickson HLP types
share numerous genetic determinants among themselves; and (iii) genetic determinants of modest TG
variation in normolipidemic population samples also underlie—to an apparently even greater degree—
susceptibility to these rare HLP phenotypes. Thus, the TG-associated Fredrickson HLP types 2B, 3, 4 and
5, although historically considered to be distinct are actually complex traits sharing among them several
common genetic determinants seen in GWAS of normolipidemic population samples.
INTRODUCTION
Genome-wide association studies (GWAS) have generated
excitement due to the new possibilities of better understanding
the genetic architecture of complex diseases (1–4), such as
hyperlipidemia (5). One concern raised about GWAS in
general is that the magnitude of genetic associations is rela-
tively modest in scale, and thus possibly of limited interest
or importance biologically or medically (1). For the quantitat-
ive trait of plasma lipoproteins, many familiar and new loci
have emerged from recent GWAS (6–14), however, the mag-
nitude of the genetic effects in normolipidemic samples were
very modest—to an extent that many medical practitioners
might question their relevance (5). One piece of evidence
that would enhance the perception of the potential clinical
value of these single nucleotide polymorphisms (SNPs)
would be demonstration of their association with disorders
that clinicians routinely diagnosis and manage.
The Fredrickson or World Health Organization Inter-
national Classiﬁcation of Diseases ontology of primary hyper-
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biochemical ‘shorthand’ by generations of physicians (15).
Most Fredrickson types (Supplementary Material, Table S1),
speciﬁcally HLP types 1, 2B, 3, 4 and 5 (MIM 238600,
144250, 107741, 144600 and 144650, respectively) feature
elevated plasma triglyceride (TG) concentration as part of
their deﬁnition (5,15–17). The exception is familial hyperch-
olesterolemia [FH; HLP type 2A (MIM 143890)], which is
often due to heterozygous mutations in LDLR encoding the
low-density lipoprotein (LDL) receptor (18). In rare instances,
single gene mutations have been found in hyperchylomicrone-
mic patients with HLP type 1, particularly homozygous
mutations either in LPL, which encodes lipoprotein lipase
(LPL), or in APOC2, which encodes its cofactor apolipopro-
tein (apo) C-II (19). Thus, the genetic bases of HLP types 1
and 2A have largely been elucidated. Furthermore, 10% of
adults with HLP type 5 have a heterozygous loss-of-function
mutation in one of several genes encoding proteins involved
in TG metabolism (20). However, most cases of HLP types
2B, 3, 4 and 5 are incompletely characterized at the molecular
genetic level, although HLP type 3 requires homozygosity for
the APOE E2 isoform as a necessary, but not sufﬁcient,
genetic condition for expression of the phenotype (5).
We previously found that: (1) APOA5 variants -1131T.C
and p.S19W are frequently present in and strongly associated
with Fredrickson types 2B, 3, 4 and 5 and also with hypertri-
glyceridemia (HTG) in general lipid clinic patients (21); and
(2) several common SNPs, found to be contributors to subtle
variation in TG concentration in normolipidemic controls,
including SNPs in APOA5, APOE, TRIB1, TBL2, GCKR and
GALNT2 were signiﬁcant determinants of HLP type 5 (22).
On the basis of these results, we hypothesized that common
variants recently associated with variation in relatively
normal plasma TG levels identiﬁed in GWAS (10–15)
would also be associated with the remaining uncharacterized
Fredrickson HLP phenotypes—namely types 2B, 3 and 4.
RESULTS
Clinical, biochemical and genetic attributes
in HLP cases and controls
Baseline demographic attributes of the 368 HLP patients and
242 normolipidemic controls are shown in Table 1. Genotype
counts and frequencies among patients and controls are shown
in Supplementary Material, Table S2. Minor (i.e. less
common) allele frequencies for each genotype in severe
HTG cases and controls are shown in Table 2. Frequencies
of each genotype did not indicate deviations from Hardy–
Weinberg equilibrium. Univariate odds ratios (ORs) for
association between SNP genotypes—assuming dominant
and recessive models—with the discrete HLP traits are
shown in Supplementary Material, Table S3.
Linkage disequilibrium and index SNPs for each locus
Pairwise linkage disequilibrium (LD) was determined across
loci (Supplementary Material, Table S4). Of the 28 variants
genotyped, 17 index genotypes were selected for further stat-
istical modeling by including only one member of a SNP gen-
otype pair for which LD was signiﬁcant and the LD correlation
coefﬁcient .0.65. Index genotypes that were selected for
multivariate regression analysis are indicated in Table 2.
Polygenic determinants of Fredrickson HLP
phenotypes: multivariate regression analysis
To assess the relationship of genotypes with HLP phenotypes,
dominant and recessive models of minor allele genotypes were
tested for each gene using univariate analysis (Supplementary
Material, Table S2). For each signiﬁcant univariate associ-
ation, either the dominant or recessive variable clearly pro-
vided the stronger association; this variable was then used in
subsequent analyses for the genotype.
The multivariate ORs for each HLP phenotype individually,
all HLP types (2A, 2B, 3, 4 and 5) and all HTG-containing
HLP types (2B, 3, 4 and 5) were calculated using the Wald
statistic in multivariate logistic regression analysis with step-
wise addition of variables, with P , 0.05 set for each step
(Table 3A and B). Each of the ﬁve models evaluated included
index genetic variables only (Table 3A), except for the model
for HLP type 3, in which APOE genotype was excluded, since
all those subjects had the E2/2 genotype. Age and sex were
included in a series of post hoc models (Table 3B).
Signiﬁcant associations are shown in Table 3A and
B. Importantly, none of the genotypes are associated with
HLP 2A, a trait that was deﬁned by elevated LDL cholesterol
with no elevated TG component. The C-statistic, which corre-
sponds to the area under the receiver–operator characteristic
curve for a diagnostic test, was between 0.75 and 0.80 for
this combination of index genotypes (Table 3A and B).
APOA5 p.S19W and -1131T.C, TRIB1 rs17321515 and
TBL2 rs17145738 were signiﬁcantly associated with HLP
types 2B, 3, 4 and 5. GCKR rs780094 was associated with
HLP types 2B and 5 only. GALNT2 rs4846914 was associated
with HLP types 4 and 5 only. LPL p.S447X was only associ-
ated with HLP type 4, LIPC rs477501 was only associated
with HLP type 2B and ANGPTL3 rs12130333 was only associ-
ated with HLP type 5. APOE non-E3 genotype was a deﬁning
feature of HLP type 3, but was also associated with HLP type
5 in the multivariate model. When all HTG-containing HLP
types were considered together, APOA5 p.S19W and
-1131T.C, TRIB1 rs17321515, TBL2 rs17145738, GCKR
rs780094, GALNT2 rs4846914 and ANGPTL3 rs12130333
were signiﬁcantly associated in the multivariate logistic
model. Inclusion of age and sex resulted in even higher
C-statistics: .0.8 in most models tested (Table 3B).
DISCUSSION
The principal novel ﬁndings in this study are: (i) several gen-
otypes that were found by GWAS to be associated with mod-
erate variation in plasma TG in samples without severe
dyslipidemia are also associated with classical HLP pheno-
types; (ii) speciﬁcally, four genotypes, namely APOA5
p.S19W and -1131C.T, TRIB1 rs17321515 and TBL2
rs17145738, were signiﬁcantly associated with HLP 2B, 3, 4
and 5; (iii) other genotypes, including APOE isoforms,
GCKR rs780094, GALNT2 rs4846914 and ANGPTL3
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of these HLP types; and (iv) genotypes contributed to a sub-
stantial portion of susceptibility to both the discrete HLP
types and to plasma TG concentrations across all HLP types.
The ﬁndings of SNPs outside of APOA5 (21) associated
with HLP types 2B, 3 and 4 are completely novel to the
current experiments, although the current results for HLP
type 5 essentially conﬁrm our previous ﬁndings (22).
Together, the previous (21,22) and current ﬁndings emphasize
the complex, polygenic nature of Fredrickson HLP types 2B,
3, 4 and 5 (5), and further demonstrate that loci identiﬁed in
GWAS of normolipidemic samples are also determinants of
hyperlipidemia.
ThespeciﬁcSNPgenotypesselectedforthisstudywerebased
on GWAS results. In each case, the allele that was associated
with the HLP phenotype in our study was also associated in
Table 1. Clinical, biochemical and genetic attributes of study subjects according to lipoprotein phenotypes
HLP type 2A HLP type 2B HLP type 3 HLP type 4 HLP type 5 Normolipidemic
Number 82 68 42 48 146 242
Percent female (%) 46.3 48.5 38.1 22.9 30.8 53.7
Age (years) 41.0+16.1 57.4+12.0 52.0+12.2 59.3+14.3 50.3+12.6 50.8+15.2
Body mass index (kg/m
2) 27.9+5.8 28.7+4.3 28.4+3.1 31.8+8.3 30.6+4.7 27.0+4.5
Plasma cholesterol (mmol/l)
Total 8.3+2.1 8.1+1.5 9.3+1.9 4.9+0.79 12.0+6.0 4.98+0.85
High density lipoprotein 1.2+0.34 1.2+0.31 1.1+0.36 0.8+0.25 0.8+0.37 1.3+0.36
Plasma triglyceride (mmol/l) 1.6+0.72 4.8+1.3 6.8+2.9 4.7+1.4 31.0+25.5 1.2+0.42
HLP, hyperlipoproteinemia.
Table 2. Candidate gene minor allele frequencies
Gene and polymorphism name Type 2A (N ¼ 82) Type 2B (N ¼ 68) Type 3 (N ¼ 42) Type 4 (N ¼ 48) Type 5 (N ¼ 146) Controls (N ¼ 242)
APOA5 p.S19W  0.067 0.118 0.167 0.083 0.188 0.052
APOA5 -1131T.C  0.079 0.081 0.155 0.177 0.191 0.048
APOA5 rs6589566 G 0.079 0.100 0.155 0.167 0.202 0.060
APOA5 rs12286037 T 0.067 0.125 0.167 0.083 0.188 0.050
BUD13 rs964184 G 0.146 0.221 0.317 0.250 0.386 0.110
BUD13 rs28927680 G 0.069 0.125 0.155 0.098 0.197 0.058
APOC3 -482C.T  0.232 0.287 0.345 0.365 0.315 0.287
TRIB1 rs17321515 G  0.396 0.324 0.345 0.385 0.346 0.492
TRIB1 rs2954029 T 0.382 0.324 0.325 0.370 0.322 0.479
TBL2 rs17145738 T  0.110 0.051 0.083 0.052 0.075 0.149
BAZ1B rs2074755 C 0.104 0.074 0.071 0.052 0.072 0.152
GCKR rs780094 A  0.389 0.529 0.147 0.385 0.531 0.393
GCKR rs1260326 T 0.409 0.449 0.452 0.396 0.551 0.400
CILP2 rs16996148 T  0.067 0.066 0.048 0.083 0.055 0.095
SF4 rs10401969 C  0.079 0.066 0.024 0.073 0.045 0.088
APOE non-E3 allele  0.159 0.272 1.000 0.281 0.281 0.207
LPL p.S447X  0.091 0.096 0.071 0.031 0.041 0.081
LPL rs10503669 A 0.079 0.088 0.060 0.021 0.038 0.081
LPL rs17482753 T 0.093 0.088 0.071 0.032 0.038 0.088
LPL rs6993414 G 0.098 0.088 0.071 0.031 0.045 0.088
ANGPTL3 rs12130333 T  0.190 0.147 0.122 0.208 0.154 0.236
ANGPTL3 rs1748195 G 0.323 0.250 0.214 0.365 0.212 0.335
GALNT2 rs4846914 G  0.384 0.412 0.405 0.510 0.497 0.374
PSRC1 rs599839 G  0.171 0.154 0.214 0.208 0.233 0.211
LDLR rs6511720 T  0.116 0.096 0.119 0.094 0.110 0.122
APOB rs693 T  0.500 0.544 0.488 0.394 0.500 0.490
SELP rs3917820 A  0.111 0.088 0.088 0.117 0.138 0.129
LIPC rs4775041 C  0.323 0.338 0.310 0.167 0.332 0.273
APOA5, gene encoding apolipoprotein A-V; BUD13, gene encoding homologue of yeast Bud13; APOC3, gene encoding apolipoprotein C-III; TRIB1,
gene encoding homologue of Drosophila Tribbles 1; TBL2 locus containing genes encoding transducin-beta-like-2 and MLX interacting protein-like
(also called carbohydrate response element binding protein [ChREBP]); BAZ1B, gene encoding bromodomain adjacent to zinc ﬁnger domain, 1B;
GCKR, gene encoding glucokinase receptor; CILP2, gene encoding cartilage intermediate layer protein 2; SF4, gene encoding splicing factor 4; APOE,
gene encoding apolipoprotein E; LPL, gene encoding lipoprotein lipase; ANGPTL3, gene encoding angiopoietin-like 3; GALNT2, gene encoding
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase; PSRC1, locus containing genes encoding proline/serine-rich
coiled-coil 1, cadherin epidermal growth factor lag seven-pass G-type receptor 1 and sortilin 1; LDLR, gene encoding low-density lipoprotein receptor;
APOB, gene encoding apolipoprotein B, SELP, gene encoding selectin P; LIPC, gene encoding hepatic lipase. Asterisk ( ) indicates index marker
selected for multivariate regression analyses (see text for Materials and Methods).
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indicates that these common—and so far mechanistically unde-
ﬁned—markers and loci are strongly and cumulatively associ-
ated with four different Fredrickson TG-associated HLP
phenotypes and four of these genotypes are common across all
types evaluated. This further suggests that rare loss-of-function
variantsinthesegenes,orinproximalgenesforwhichtheSNPs
are markers, might also be determinants of severe HTG. Rese-
quencing of genes marked by these SNPs should be considered
inpatientswithHLP.Butalthoughtheﬁndingsclearlylinkthese
genotypes with dyslipidemia, other factors must also be impor-
tant, since genotypes studied here cumulatively accounted for
only 20% of variation in plasma TG concentrations.
Our ﬁndings are consistent with the emerging model that at
the extremes of a complex genetic trait, such as patients with
Fredrickson HLP phenotypes are found the cumulative contri-
butions of multiple common alleles. Furthermore, some
patients, such as most of those with HLP types 1 and 2A, and
10%ofthosewithHLPtype5(20),haverareloss-of-function
mutationswithlargeeffectsizes.Wedonotsuggestthatthevar-
iants studied here are directly causative for HLP phenotypes.
However, the present study substantially increases the pro-
portion of patients with Fredrickson HLP phenotypes who
have a signiﬁcantly associated underlying genetic predisposi-
tion. The ﬁndings reinforce that the genetic contribution to
most of the Fredrickson HLP phenotypes is complex, but also
suggest that additional genes or non-genetic factors may still
play an important role. These might be found by performing
GWAS in HLP samples themselves, as it remains possible
that there might be certain determinants of these abnormal
phenotypesthatarenotnecessarilydeterminantsofplasmalipo-
protein variation within the normal range. Furthermore, the
results show that signiﬁcant associations can be identiﬁed by
studying a relatively small number of subjects with extreme
values of a quantitative lipoprotein trait. Finally, re-sequencing




We studied 386 consecutive unrelated subjects of European
ancestry from a tertiary referral lipid clinic. Patients under-
went a complete medical history and examination; basic clini-
cal, biochemical and demographic variables were collected.
Normolipidemic adult controls were taken from the European
subgroup of the Study of Health Assessment and Risk in
Ethnic groups, a survey of cardiovascular risk factors in Cana-
dian sub-populations (23) together with healthy population-
based controls from Ontario. Using a validated sampling strat-
egy (23), households of Caucasian ethnicity within essentially
the same geographic locale as the catchment area from which
the patients were referred were randomly selected and mailed
an introductory letter, followed by up to 12 telephone calls
inviting the individual with the earliest date of birth from
the household to participate. All patients provided informed
consent for DNA analysis (University of Western Ontario
Institutional Review Board protocol #07920E).
Table 3. Multivariate logistic regression analysis of TG-associated SNPs
HLP type 2B HLP type 3 HLP type 4 HLP type 5 All HTG types
(A) In Fredrickson HLP types
APOA5 p.S19W dominant 4.12 (1.84, 9.23) 6.47 (2.63, 15.9) 3.69 (1.35, 10.1) 7.35 (3.82, 14.2) 5.35 (2.97, 9.63)
APOA5 -1131T.C dominant 2.40 (1.02, 5.61) 4.56 (1.85, 11.2) 6.13 (2.62, 14.3) 5.34 (2.84, 10.0) 3.99 (2.31, 6.87)
TRIB1 rs17321515 G recessive 0.14 (0.05, 0.42) 0.15 (0.04, 0.68) 0.23 (0.07, 0.71) 0.36 (0.18, 0.71) 0.24 (0.14, 0.43)
TBL2 rs17145738 T dominant 0.24 (0.10, 0.59) 0.36 (0.14, 0.98) 0.19 (0.06, 0.57) 0.28 (0.15, 0.55) 0.30 (0.18, 0.50)
GCKR rs780094 A recessive 2.74 (1.41, 5.32) NS NS 2.38 (1.31, 4.31) 2.20 (1.34, 3.62)
LIPC rs477501 C dominant 2.04 (1.14, 3.66) NS NS NS NS
GALNT2 rs4846914 G recessive NS NS 3.29 (1.36, 7.96) 2.98 (1.53, 5.82) 2.43 (1.36, 4.33)
LPL S447X dominant NS NS 0.17 (0.04, 0.86) NS NS
ANGPTL3 rs12130333 T dominant NS NS NS 0.56 (0.33, 0.94) 0.61 (0.41, 0.92)
APOE non-E3 NS Not tested NS NS 1.99 (1.38, 2.96)
SF4 rs10401969 C dominant NS NS NS NS NS
C-statistic 0.767 0.749 0.778 0.806 0.790
(B) In Fredrickson HLP types with age and sex
APOA5 p.S19W dominant 5.15 (2.15, 12.36) 6.41 (2.49, 16.5 4.51 (1.42, 14.3) 7.22 (3.59, 14.5) 5.23 (2.81, 9.75)
APOA5 -1131T.C dominant 3.30 (1.26, 8.63) 5.62 (2.11, 14.9) 11.7 (4.23, 32.7) 6.86 (3.38, 13.9) 4.98 (2.70, 9.18)
TRIB1 rs17321515 G recessive 0.13 (0.04, 0.41) 0.15 (0.03, 0.66) 0.19 (0.06, 0.65) 0.37 (0.19, 0.74) 0.26 (0.14, 0.44)
TBL2 rs17145738 T dominant 0.22 (0.09, 0.57) 0.28 (0.10, 0.80) 0.16 (0.05, 0.53) 0.24 (0.12, 0.49) 0.25 (0.15, 0.43)
GCKR rs780094 A recessive 2.33 (1.16, 4.70) NS NS 2.35 (1.26, 4.40) 2.12 (1.26, 3.58)
LIPC rs477501 C dominant 2.34 (1.26, 4.35) NS NS NS NS
GALNT2 rs4846914 G recessive NS NS NS 3.10 (1.49, 6.46) 2.58 (1.37, 4.82)
LPL S447X dominant NS NS 0.13 (0.02, 0.74) NS NS
ANGPTL3 rs12130333 T dominant 0.50 (0.26, 0.96) NS NS 0.50 (0.29, 0.86) 0.55 (0.36, 0.85)
APOE non-E3 NS Not tested NS NS 1.78 (1.17, 2.72)
SF4 rs10401969 C dominant NS NS NS NS NS
Male sex NS 2.23 (1.03, 4.87) 6.38 (2.63, 15.5) 2.42 (1.43, 4.10) 2.16 (1.43 3.28)
Age .60 years 2.57 (1.35, 4.90) NS 2.75 (1.25, 6.05) NS NS
C-statistic 0.805 0.778 0.855 0.833 0.813
HTG, hypertriglyceridemia; NS, not signiﬁcant.
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by HLP phenotype
Plasma lipoprotein proﬁles were determined as described for
adult (age .18 years) lipid clinic patients (21) and for normal
controls (23). Subjects were classiﬁed as having familial
hypercholesterolemia(FH;HLPtype2A)basedonthepresence
of deﬁnite diagnostic criteria (24), which in all cases included
demonstration of heterozygosity for a disease-causing
mutation.SubjectswereclassiﬁedashavingHLPtype2B(com-
bined hyperlipidemia) on the basis of both cholesterol and TG
higher than age- and sex-speciﬁc 95th and 90th percentile
values, respectively, together with the presence of cholesterol
or TG higher than age- and sex-speciﬁc 90th percentile values
in a blood relative. Subjects were classiﬁed as having HLP
type 3 (dysbetalipoproteinemia) based on the presence of an
APOE E2/E2 homozygous genotype, TG exceeding age- and
sex-speciﬁc 90th percentile values and/or documentation of a
ratio of very-low density lipoprotein cholesterol to TG  0.30,
determined as described (21). Subjects were classiﬁed as
having HLP type 4 (primary HTG) based on TG concentrations
exceeding age- and sex-speciﬁc 90th percentile values, but not
exceeding 10 mmol/l, with no documented chylomicronemia
and absence of other lipoprotein phenotypes. Subjects were
classiﬁed has having HLP type 5 (mixed hyperlipidemia)
based on fasting plasma TG .10 mmol/l documented on  2
occasions with documented chylomicronemia. We excluded
children with fasting plasma TG .10 mmol/l with documented
chylomicronemia and homozygous or compound heterozygous
mutations in LPL or APOC2.
DNA analysis
DNA was extracted as described (25). Markers were selected
based on their association (or the association of their genetic
locus) with plasma TG in at least two reports (6–14). APOA5
p.S19W and -1131C.T (dbSNP rs662799), APOC3 482C.T,
APOE isotypes (26) and LPL p.S447X (20) were genotyped as
described. Genotypes of APOA5 rs6589566 and rs12286037,
BUD13 rs964184 and rs28927680, TRIB1 rs17321515 and
rs2954029, TBL2 rs17145738 and BAZ1B rs2074755, GCKR
rs780094 and rs1260326, CILP2 rs16996148, SF4 rs10401969,
LPL rs10503669, rs17482753 and rs6993414, ANGPTL3
rs12130333 and rs1748195, GALNT2 rs4846914 and LIPC
rs4775041 were determined using TaqMan based protocols
and reagents (Applied Biosystems). We also genotyped LDL
cholesterol (not TG)-related SNPs PSRC1 rs599839, LDLR
rs6511720, APOB rs693 and SELP rs3917820 using TaqMan
based protocols and reagents (Applied Biosystems). For
APOE, presence or absence of the common E3/3 genotype
was evaluated, except in HLP type 3, since APOE E2/2
isotype was considered to be part of the phenotypic deﬁnition.
A random 5% of genotypes were repeated on a different day;
the concordance rate exceeded 99.9% for all markers studied.
Statistical analysis
The two-sample t-test was used to compare the difference
between case and control groups for quantitative traits,
although Pearson’s chi-square test was used to compare
discrete traits with exact P-values obtained whenever cell
sizes ,5. Deviations of genotype frequency from the Hardy–
Weinberg assumption were assessed using a chi-square test.
Maximal likelihood LD was estimated as described (27). To
assess the relationship of genotypes with HLP phenotypes,
dominant and recessive models of minor allele genotypes
were tested for each gene. Since we were most interested in
the polygenic nature of these traits, we used a multiple logistic
regression model with backward elimination to assess the joint
effects of SNP genotypes on HLP phenotypes. For a genotype
with frequency 0.20, the study sample afforded statistical
power (alpha error level ¼ 0.05) to detect 1.4-, 1.6-, 1.8- and
2.0-fold increases in frequency of 59.1, 85.7, 96.9 and 99.9%,
respectively. Statistical signiﬁcance was taken at a two-sided
P-value ,0.05 for all comparisons. Most analyses were per-
formed using SAS version 9.1 (SAS Institute), whereas exact
tests were performed using StatXact8 (Cytel Inc.).
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